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Expression of CD44, particularly of certain splice variants, has 
been linked to tumor progression and metastasis formation in a 
number of different animal and human cancers. Because human 
cutaneous melanoma is among the most aggressive human 
cancers, we explored expression of CD44 isoforms (CD44v) in 
lesions of melanocytic tumor progression. In addition, by RT- 
PCR and FACS analysis we assessed CD44v RNA species and 
cell surface expression of CD44v in cultured melanocytes 
isolated from human foreskin and in a panel of 2 non-, 2 
sporadically and 2 highly metastatic human melanoma cell lines. 
We observed that all melanocytic lesions examined showed 
strong uniform expression of standard CD44 (CD44s) epitopes« 
We did not detect CD44v6 expression in the melanocytic 
lesions. However, CD44 isoforms containing v5 or vIO were 
differentially expressed. V5 was expressed in 16%, 0%, 20%, 
67% and 58% of common nevi, atypical nevi, early primary 
melanomas (<1.5 mm), advanced primary melanomas (>1.5  
mm) and metastases, respectively» and hence was related to 
tumor progression* In contrast, CD44vl0 was expressed in all 
common nevi, whereas part of the atypical nevi and most 
primary melanomas and metastases lacked vIO. CD44v RNA 
patterns were closely similar in cultured melanocytes and all 
melanoma cell lines. Melanocytes expressed high levels of 
CD44s but no CD44v, whereas all melanoma cell lines ex­
pressed CD44v at the surface. Interestingly, expression of v5 
was strongly increased in the highly metastatic cell lines. Our 
results suggest a role for CD44 variant domains, particularly v5 
and v 10, in human melanocytic tumor progression.
© 1995 Wiley-Liss, Inc.
During tumor progression, a subset of cells acquires meta­
static properties, presumably through a series of genetic 
alterations. As a result, cells detach from the primary tumor, 
penetrate the basement membrane into the connective tissue 
and invade adjacent structures, including lymph and blood 
vessels. The tumor cells are subsequently transported to sites 
of metastatic outgrowth via lymph and/or blood. Loss of 
adhesive functions and gain of new adhesive functions are 
thought to play a crucial role in this metastatic cascade.
CD44, a heterogenous family of molecules with putative 
functions in cell-cell and cell-matrix interaction, has been 
linked to tumor progression in a number of malignancies. In 
human non-Hodgkin's lymphomas (Horst et al, 1991) and in 
adenocarcinomas of the colon (Wielenga et ai, 1993), stomach 
(Mayer etal, 1993) and breast (Joensuu etal, 1993) expression 
of CD44 was found to be related to tumor dissemination 
and/or unfavorable prognosis. In a rat model highly metastasiz­
ing adenocarcinoma cell lines express splice variants of the 
CD44 glycoprotein. These variants differ from the standard 
CD44 molecule in that they contain additional peptide do­
mains inserted into the extracellular portion of the transmem­
brane protein. Some of these variants play a causal role in the 
metastatic process (Gtinthert et al, 1991). Co-injection of 
variant-specific monoclonal antibodies (MAbs) with the metas­
tasizing cells led to retardation or even complete block of 
metastatic spread in vivo (Seiter et al, 1993). Moreover, 
over-expression of specific CD44 variants in non-metastasizing 
tumor cell lines induced metastatic behavior (Gtinthert et al,
1991). CD44 variants, including homologues of those that 
confer a metastatic phenotype to rat carcinomas, have been 
found to be over-expressed in human tumors, including aggres­
sive non-Hodgkin’s lymphomas and colorectal carcinoma (Wie­
lenga et al, 1993; Koopman et al., 1993). The fact that 
malignant melanomas are among the most aggressive human 
tumors prompted us to explore the expression of CD44 splice 
variants in human cutaneous melanocytic tumor progression in 
vivo and in cultured normal human melanocytes and mela­
noma cell lines with different metastatic properties after s.c. 
inoculation into nude mice.
MATERIAL AND METHODS
Antibodies
MAbs directed against the variant portions of CD44 were 
VFF4 anti-CD44v6 (IgG2b); VFF7 and VFF18 anti-CD44v6 
(both IgGj); VFF8 anti-CD44v5 (IgGO and VFF14 and VFF16 
anti-CD44vlO (both IgGO (Wielenga etal., 1993; Koopman et 
a l} 1993). The VFF series of antibodies were kindly provided 
by Drs. E. Patzelt and G. Adolf, Bender-Wien, Vienna, 
Austria. The MAb against an epitope on the constant portion 
of the extracellular domain of CD44 was NKI-P1 (Pals et ai, 1989). 
Specificity of the MAbs is schematically shown in Figure 1.
Tissues
Human melanocytic lesions were selected from the files of 
the Department of Pathology, University Hospital, Nijmegen, 
The Netherlands, and the Department of Dermatology, Univer­
sity Hospital, Wurzburg, Germany, and tested for expression 
of CD44s and CD44v, employing the MAbs described above. 
Based on histopathologic examination of paraffin sections, 
lesions were divided into 5 classes: common nevocellular nevus 
(n = 19), atypical (dysplastic) nevocellular nevus (n = 9), 
early primary cutaneous melanoma {i.e., tumor thickness <1.5 
mm; n = 10), advanced primary cutaneous melanoma (Le., 
tumor thickness >1.5 mm; n = 9) and melanoma metastasis 
(n = 19).
Immunohistochemistiy
Immunoperoxidase staining was performed as described 
previously (Danen etal, 1993). Briefly, 4 fxm cryostat sections 
were fixed in acetone for 10 min, washed in PBS and incubated 
with the primary antibody for 1 hr. Bound MAbs were 
visualized using the peroxidase-based Vectastain elite ABC 
Kit (Vector, Burlingame, CA) and amino-ethyl-carbazole. 
Lesions were designated “positive’5 when they were estimated 
to show staining in more than 10% of the melanocytic cells.
4To whom requests for reprints and correspondence should be 
addressed, at the Department of Pathology, Academic Medical Cen­
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F igure 1 - (a) Schematic representation of the CD44 gene. Open boxes indicate exons that are spliced out of the “standard” type of 
CD44. TM, transmembrane region, (b) Schematical representation of the CD44 protein with location of the epitopes which are 
recognized by the MAbs NKI-P1, VFF4, VFF7, VFF8, VFF14, VFF16 and VFF18. Anti-variant antibodies were raised against a 
bacterialiy expressed fusion protein encoded by pGEX CD44v HPKII (v3 to vIO). Dark area, “standard CD44”; vl-vlO, domains 
encoded by variant exons.
Cell lines and cell cultures
The human melanoma cell lines 530 and IF 6 (non­
metastatic upon s.c. injection in nude mice), M14 and MEL57 
(sporadically metastatic upon s.c. injection in nude mice) and 
MV3 and BLM (frequently metastatic upon s.c. injection in 
nude mice; Danen et ai, 1993) were studied for expression of 
CD44 variants. The cell lines were grown in D M EM  (G IBCO 
BRL, Grand Island, NY) supplemented with 1 mM glutamine, 
10% (v/v) heat-inactivated FCS (Hyclone, Logan, UT) and 
antibiotics. Primary melanocytes were isolated from human 
foreskin and cultured in Ham’s F10 (Flow, Irvine, UK) 
supplemented with 2% Ultroser-G synthetic serum (G IBCO), 
glutamate, penicillin, streptomycin, 0.1 mM IBM X  (Sigma, St. 
Louis, M O) and 16 nM phorbol 12-myristate 13 acetate (PMA; 
Sigma) for a maximum of 5 passages, as described previously 
(Danen et al, 1993).
Flow cytometiy
Cells were sequentially incubated in PBS containing 1% 
BSA and 0.02% sodium azide with appropriate dilutions of the 
various antibodies, followed by incubation with biotin- 
conjugated rabbit-anti-mouse Ig and phycoerythrin-labeled 
streptavidin (Dakopatts, Glostrup, Denmark). Fluorescence 
was measured by a FACScan flow cytometer (Becton Dickin­
son, Mountain View, CA).
Reverse transcriptase polymerase chain reaction
Cells (5 to 10 x 107) were harvested, washed and lysed by 
the addition of 0.2 ml of RNAzol (Campro Scientific, 
Veenendaal, The Netherlands) per 106 cells. Total RN A  was 
extracted by adding 0.2 ml chloroform per 2 ml of cell lysate. 
After centrifugation at 12,000# for 15 min (4°C) the aqueous 
phase was transferred to a fresh tube and RN A  was precipi­
tated using isopropanol at -20°C for 45 min. Isolated RN A  
was stored at -80°C in 70% ethanol until use; 2 |xg aliquots of 
total RN A  were used to synthesize cDNA using an oligo dT 
primer with DNA reverse transcriptase, according to the 
protocol provided with the GeneAmp RNA-PCR kit (Perkin 
Elmer Cetus, Norwalk, CT). Amplification of cDNA was 
performed using CD44 5' constant and CD44 3' constant 
primers corresponding to positions 513-540 and 900-922 of 
the standard CD44 sequence described by Screaton el a i
(1992). Amplification was performed in 35 cycles (30 sec, 94°C;
1 min, 55°C and 2 min, 72°C) in a microwave-based Ampliwave 
DNA  incubator (Kreatech, Amsterdam, The Netherlands). 
PCR products were analyzed on a 2% agarose gel (Brunsch- 
wig, Amsterdam, The Netherlands) containing ethidium bro­
mide, subsequently transferred to nylon filters (Gene Screene 
Plus, NEN, Boston, M A) and hybridized with a 5' constant 
CD44-specific oligonucleotide probe (position 513-540; CA 
GAC CTG CCC AAT  GCC TTT GAT G G A  CC) or exon v5 
(position 1164-1184; AT G G C  ACC ACT GCT TAT GAA G), 
exon v6 (position 1322-1346; TGG TTT GGC AAC A G A  
TGG CAT GAG  G), exon v7 (position 1443-1464; CA AGC 
CCA G A G  GAC A G T  TCC TG) and exon vIO (position 
1799-1817; CT CAT TAC CCA CAC ACG AA) specific
oligonucleotide probes labeled with gamma(ATP)32P (Amer- 
sham, Den Bosch, The Netherlands) using polynucleotide 
kinase (Boehringer Mannheim, Germany).
RESULTS
Expression of CD44 variants in common and atypical 
nevocellular nevi and malignant melanomas
Immunohistochemical studies demonstrated differential ex­
pression of the various CD44 epitopes in melanocytic lesions 
(Figs. 2, 3). In all types of lesion, there was a strong homo­
genous expression of CD44 proteins, determined by the 
pan-CD44 MAb NKI-Pl directed against an epitope on the 
N H 2 terminal constant part of CD44. By contrast, expression 
of epitopes encoded by v6 was not observed with any of the 3 
MAbs used, although normal epidermal keratinocytes present 
in all tissue sections strongly stained (not shown).
Interestingly, there was a marked difference in the expres­
sion of v5 and vIO in the different types of melanocytic lesion. In the 
lesions that were positive for v5 or vIO, a heterogeneous staining 
pattern was observed with 25-100% positive melanocytic cells.
V5 was detected in only a low percentage of the common 
and atypical nevi and early primary melanomas, i.e., in 3/19 
(16%), 0/9 (0%) and 2/10 (20%), respectively (Figs. 2, 3). 
However, the majority of the advanced primary melanomas 
(6/9, 67%) and melanoma metastases (11/19, 58%) expressed 
CD44v5 (Figs. 2, 3). Hence, over-expression of v5-containing 
CD44 isoforms is strongly related to tumor progression (x 
trend 1 d.f. =  12.82;;? = 0.0005).
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F ig u r e  2 - Expression of CD44v on human melanocytic lesions, n, nevus cells; m, melanoma cells; s, stroma. (a) Common melanocytic 
nevus strongly positive for CD44s (NKI-P1). (.b and c) Comparable region of the same lesion as in (a) negative for CD44v5 (VFF8) (b)
and positive for CD44vlO (VFF14) (c). (d) Atypical nevus strongly positive foi 
lesion as in (cl) negative for CD44v5 (VFF8) (e) and positive for CD44vlOl0 (VFF14) (f). (g and h) Early primary melanoma strongly 
. (i) Advanced primary melanoma strongly positive for CD44s 
¡itive for CD44v5 (‘VFF8') (i) and negative for CD44vlO (VFF14)
positive for CD44s (NKI-P1) (g) and negative for CD44v5 (VFF8) (h).
(NKI-P1). (j and k) Comparable region from the same lesion as in (i) positi ) j  
(k). (I) Melanoma metastasis strongly positive for CD44s (NKI-P1). (m andn) Comparable region from the same lesion as in (I) positive 
for CD44v5 whereas the stroma cells are negative (VFF8) (m) and negative for CD44vlO (VFF14) (n). Bar: 20 jjliti.
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F ig u r e  3 - Expression of CD44v5 (VFF8), CD44v6 (VFF7) and CD44vlO (VFF14) in human melanoma progression. Bars indicate 
the percentage of positive tumors.
VIO-encoded epitopes were also differentially expressed in 
the various types of melanocytic lesion. The pattern of expres­
sion of vlO, however, was strikingly different from that of v5. 
VI.0 was detected in 100% of common nevi (19/19), in 67% of 
atypical nevi (6/9), in 10% of early primary melanomas (1/10), 
in 11% of advanced primary melanomas (1/9) and in 32% of 
the melanoma metastases (6/19) (Figs. 2,3). Hence, malignant 
transformation of melanocytes is often associated with a loss of 
exon vlO expression (x2 trend 1 d.f. = 9.25;p = 0.026).
Expression of CD44 isoforms on cultured melanocytes and 
melanoma cell lines
We next assessed the expression of CD44 isoforms on 
cultured normal melanocytes isolated from human foreskin as 
well as on a panel of human melanoma cell lines that are non- 
(IF6, 530), sporadically (M14, MEL57) and highly (BLM, 
MV3) metastatic after s.c. inoculation into nude mice. Cul­
tured normal melanocytes were found to express high levels of 
standard CD44, with a mean relative fluorescence intensity of 
approximately 5 x 103 (not shown). Epitopes encoded by v5, v6 
and vlO were hardly or not detectable on melanocytes (Fig. 4).
The human melanoma cell lines also showed a strong 
expression of standard CD44 epitopes (not shown). This 
expression was independent of the metastatic phenotype of the 
cell lines. Interestingly, however, expression of v5- and v6- 
containing CD44 splice variants was variable, and expression 
of v6 and particularly v5 related to the metastatic potential of 
the cell lines (Fig. 4). Thus expression CD44v6 in the highly 
metastatic cell lines was much higher than in the non-metastatic 
cell lines. High expression of CD44v6 was also observed in one of 
the sporadically metastatic lines (i.e.} MEL57). Furthermore, 
CD44v5 was weakly expressed on the non- and sporadically 
metastatic cell lines, but expression on the highly metastatic 
cell lines was 5- to 10-fold higher. All melanoma cell lines 
weakly expressed CD44vlO. The difference in culture condi­
tions of melanoma cell lines and primary cultured melanocytes 
did not influence the CD44 expression profile on melanocytes 
and melanoma cell lines (data not shown).
RT-PCR analysis demonstrates multiple CD44 splice variants
To gain insight into the diversity and structure of the CD44 
splice variants expressed in human melanocytes and mela­
noma cell lines, RN A  prepared from these cells was subjected 
to RT-PCR amplification using primers corresponding to 
sequences of the 5' and the 3' standard constant region of 
CD44. W ith these primers a major PCR product of approxi­
mately 450 bp was obtained from the normal melanocytes as 
well as from the melanoma cell lines (Fig. 5a). The size of this 
product corresponds to that expected for the standard CD44 
message. In addition, up to 6 minor bands of approximately 
530, 580, 615, 660, 850 and 1,100 bp were obtained from the
melanoma cell lines. Human cultured melanocytes gave rise to 
5 minor bands of 530, 580, 660,850 and 1100 bp (Fig. 5a).
Hybridization of the PCR products of melanocytes and 
melanoma cell lines with specific oligonucleotide probes (Fig. 
5b-f) showed that ail contained one to several splice variants 
with v6, v7 and vlO, Except for M14, all melanoma cell lines 
contained splice variants with v5, whereas melanocytes did not 
hybridize with v5-specific probes. In general, the patterns 
obtained with the different cell lines were very similar.
DISCUSSION
Adhesion molecules mediating cell-cell or cell-matrix inter­
actions are involved in several steps of the metastatic cascade. 
In malignant melanoma increased expression of integrins a2pl 
(Brocker et a l, 1985), «3(31 (Natali etal, 1993), a5pl (Danen 
et al, 1994) and a;v|33 (Seftor et a l} 1993) and of ICAM1 
(Johnson et al, 1989) and decreased expression of integrin 
a6p l (Natali et al, 1991) have been reported to correlate with 
tumor progression. Furthermore, functional studies implicate 
integrin «5(31 and ctv(33 in melanoma cell proliferation and 
invasion (Seftor etal, 1993).
Several studies show a correlation between expression of 
members of the CD44 family of adhesion molecules and tumor 
progression in human non-Hodgkin’s lymphoma (Horst et al, 
1991) and carcinoma (Wielenga et al, 1993). For human 
melanoma, a correlation has been reported in sublines from a 
single cell line between high CD44 expression and metastatic 
property, but in a large panel of different human melanoma 
cell lines no such correlation was confirmed (Eastetal, 1993). 
In addition, CD44 is strongly expressed in all stages of human 
melanocytic tumor progression in vivo (Moretti et al, 1993). 
Our finding of comparable levels of CD44s on the surface of 
normal human melanocytes and melanoma cell lines with 
different metastatic capacities confirms earlier findings that 
CD44 expression does not correlate with the metastatic capa­
city of melanoma cells (East et a l, 1993). Moreover, in line 
with previous reports (Moretti et al, 1993) we also find that 
CD44s is strongly expressed in all stages of melanocytic tumor 
progression in vivo. Hence, expression of CD44s appears to be 
independent of the presence of a malignant or metastatic 
phenotype. However, functional studies have provided evi­
dence for a role for CD44 in human melanoma cell motility 
and invasion (Faassen et al, 1992), and we have found that a 
combination of high production of hyaluronate and expression 
of “active” CD44, mediating adhesion to hyaluronate, corre­
lates with the metastatic capacity of human melanoma cell line 
(data not shown).
Currently, no evidence exists for the presence of CD44 
splice variants in human melanoma. Therefore, in the present
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F ig u re  4 - Expression of CD44v5 (VFF8), CD44v6 (VFF7) and CD44vlO (VFF14) on cultured melanocytes and melanoma cell lines 
which are non-metastatic (1F6,530), sporadically metastatic (M14, MEL57) or frequently metastatic (BLM, MV3). Binding of different 
antibodies was measured by FACS. Results show mean fluorescence intensity. Negative controls have been subtracted.
study we have investigated expression of CD44 variants (t) in 
lesions representing various stages of human melanocytic 
tumor progression in vivo and (ii) in a panel of human 
melanoma cell lines with different metastatic potential after 
s.c. inoculation into nude mice.
In contrast to CD44s, CD44 isoforms are differentially 
expressed. Expression of CD44 isoforms containing v5 is not 
found on normal human melanocytes, but v5 is expressed on 
human melanoma cell lines and is strongly enhanced in the 
highly metastatic cell lines. In addition, v5 is expressed in a 
very low percentage of benign melanocytic lesions and early 
primary melanomas, whereas it is expressed in the majority of 
advanced primary melanomas and melanoma metastases. Thus 
enhanced expression of CD44v5 is related to high metastatic 
potential of human melanoma cell lines and correlates with 
human melanocytic tumor progression in vivo. Interestingly, 
CD44v5 is also induced in human colorectal tumor progression 
(Wielenga et al, 1993). Similar to this type of cancer, where v5 
is already expressed in early stages of adenoma, v5 can also be 
detected in a few benign melanocytic nevi. However, in 
contrast to colorectal tumor progression, the transition from 
early primary melanoma to the highly aggressive stage of 
advanced primary melanoma is attended by a marked increase 
of the percentage of v5-positive lesions. Gastric diffuse-type 
adenocarcinomas and their metastases also express CD44v5 
and are devoid of v6 as well (Heider et al., 1993).
CD44v6-containing isoforms have been related to tumor 
progression in human colorectal carcinomas and malignant 
lymphomas (Wielenga et al., 1993; Koopman et al, 1993). 
Moreover, v6-containing isoforms have been shown to play a 
causal role in metastasis of rat pancreatic carcinoma cells 
(Giinthert et al, 1991; Seiter et al, 1993). However, by 
immunohistochemical staining of malignant melanomas and 
melanoma metastases, we do not detect any expression of 
CD44v6. This lack of CD44v6 expression contrasts with the 
results obtained in the 6 human melanoma cell lines, which all 
express v6. We have no explanation for the discrepancy in 
CD44v6 expression between cultured cell lines and fresh 
human malignant melanomas. Expression of v6 on the mela­
noma cell lines may be induced by the in vitro culture 
conditions. Alternatively, the v6 epitope might be masked by 
ligand binding or alterations in the conformation of the CD44 
molecule in situ.
In complete contrast to expression of v5, we find that 
expression of CD44vlO is inversely correlated to melanocytic 
tumor progression in vivo. Most metastases lack expression of 
this variant, and in line with this finding, a very low surface 
expression of CD44vlO is found on all melanoma cell lines 
tested, which were originally generated from metastases.
At the RNA level, the patterns of CD44 splice variant 
expression are closely similar in the various cell lines. This
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F igure  5 - Southern blot analysis of RT-PCR amplification products from specimens of cultured melanocytes isolated from human 
foreskin, and non-metastatic, sporadically metastatic and frequently metastatic human melanoma cell lines, (a) PCR products obtained 
with CD44-specific primers 5' and 3' of the variant part were resolved on 2% agarose containing ethidium bromide and visualized under 
UV light. The bright 450 band present in all melanoma cell lines and in the cultured melanocytes corresponds to the expected standard 
CD44 amplification product. Expression of several larger splice variants is seen in the cultured melanocytes and all cell lines, (b-f) After 
transfer of PCR products to a Hybond N+ membrane the same filter was hybridized consecutively to (b) standard CD44, (c) exon v5, (cl.) 
exon v6, (e) exon v7 and (f) exon vlO CD44-specific probes.
finding is remarkable since the cell lines studied are mutually 
unrelated. Hence, the splicing patterns observed do not 
represent idiosyncratic changes of an individual clone but may 
represent a tissue- or tumor-type-specific quality.
The functional consequence of insertion of various exons 
into the CD44 molecule remains unknown. It may be specu­
lated that the ligand-binding specificity is altered. The 90 kDa 
CD44s isoform (CD44H) expressed on most cells binds hyaluro- 
nate (Stamenkovic et aL, 1991). For hyaluronate binding of 
CD44E, an isoform that contains a 132 amino acid-inserted 
domain, available data are conflicting (Stamenkovic et al., 
1991; He et al, 1992). All of our cell lines, including melano­
cytes, express the 90 kDa CD44s molecule, and CD44- 
mediated attachment to hyaluronate observed for melanocytes 
1F6, Mel57, BLM and MV3 (data not shown) is probably via 
this isoform. Therefore, in this system we cannot look into the 
role of the splice variants in attachment to hyaluronate. 
Further studies are needed to provide more insight in this 
matter.
Taken together, we observed that an increase of CD44v5 
and a decrease of CD44vlO expression is related to melano- 
cytic tumor progression i?t vivo and that enhanced expression 
of CD44v5 is related to the metastatic capacity of melanoma 
cell lines. Our findings suggest a role for CD44v5 and CD44vl0 
in human melanocytic tumor progression and melanoma 
metastasis.
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